Prelude Therapeutics Inc (PRLD) Cash Flow Statement
Prelude Therapeutics Inc (PRLD) generated -$33.3M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$33.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PRLDPrelude Therapeutics IncFollow PRLD — free
—
Price chart with a free account
- Market cap
- 289.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -102.9 | -56.3 | -33.3 | |
| Capital expenditure | 0.8 | 0.1 | -0.0 | |
| Free cash flow | -103.7 | -56.4 | -33.3 | |
| Stock-based compensation | 21.3 | 11.9 | — |
USD millions · SEC XBRL
Prelude Therapeutics Inc — questions
- What is Prelude Therapeutics Inc's operating cash flow?
- -$33.3M over the twelve months to 2026-06-30.
- How much does Prelude Therapeutics Inc spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Prelude Therapeutics Inc's free cash flow?
- -$33.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Prelude Therapeutics Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.